Drugs / OSI-211
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00046800 | Sep 2002 → Mar 2003 | ovarian neoplasm | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT00046787 | Sep 2002 → Feb 2003 | small cell lung carcinoma | Astellas Pharma Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OSI-211 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00046787 ↗ |
| Known as | Liposomal Lurtotecan | “OSI-211 (Liposomal Lurtotecan)” NCT00046787 ↗1“OSI-211 (Liposomal Lurtotecan)” NCT00046800 ↗ |